A Phase 2 interventional study of Sarilumab in Juvenile Idiopathic Arthritis, sponsored by Sanofi. Completed at 30 sites in 15 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-10-15.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Arthritis, Juvenile with a site in Poland — 7 open to participants now, 8 under way, 7 of them phase 3. Arthritis, Juvenile · Poland.
Among the 29 studies in Arthritis, Juvenile with a site in Poland, this one is the 13th largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2016, is the only one in phase 2, and was the 14th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →7 of the 29 studies in Arthritis, Juvenile with a site in Poland are open now. Recruiting first, the newest first:
Alfasigma S.p.A. · Sites in Poland, Belgium, Czechia and 6 more countries
Ages 8–18
UCB Biopharma SRL · Sites in Poland, Canada, France and 3 more countries
Ages 2–18
Janssen Research & Development, LLC · Sites in Poland, United States, Argentina and 15 more countries
Ages 3+
AbbVie · Sites in Poland, United States, Australia and 6 more countries
Ages 5–17
Amgen · Sites in Poland, Belgium, France and 11 more countries
Ages 5–17
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 24
First in 2008; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 102 is above the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 93 across the 28 interventional studies, 3,500 across the 1 observational. Of the 21 that completed or were terminated, 18 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 29 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 2 studies filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
1 of the studies in Arthritis, Juvenile with a site in Poland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07554495Phase 3Alfasigma S.p.A.Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies in Arthritis, Juvenile with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To describe the pharmacokinetic (PK) profile of sarilumab in participants aged 2-17 years with Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA) in order to identify the dose and regimen for adequate treatment of this population
Secondary Objective:
To describe the pharmacodynamic (PD) profile, the efficacy and the long-term safety of sarilumab in participants with pcJIA.
For 73 participants enrolled in the dose-finding and second portions, the total study duration per participant was up to 166 weeks that consists of a 4- week screening, a 12-week core treatment phase, a 144-week extension phase, and a 6-week post-treatment follow-up. For 29 participants enrolled in the third portion, the total study duration per participant was up to 106 weeks that consists of a 4- week screening, a 12-week core treatment phase, a 84-week extension phase, and a 6-week post-treatment follow-up.
Inclusion criteria :
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received one of three ascending dose regimens of sarilumab by subcutaneous (SC) injection based on body weight. All the participants received the selected dose regimen once this was identified. Sarilumab was given during 12-week core treatment phase followed by an extension treatment phase (144 weeks for 73 participants enrolled in dose-finding and second portions and 84 weeks for approximately 29 participants enrolled in third portion)
Drug: Sarilumab
Pharmaceutical form:Solution Route of administration: Subcutaneous
Also known as: SAR153191 (REGN88)
Maximum Serum Concentration (Cmax) of Sarilumab at Week 12
The Cmax was defined as maximum serum concentration. The values reported are mean and standard deviation.
Time frame: Pre-dose on Days 1, 3, 5, 8, 12 and Weeks 2, 4, 8 and 12
Area Under the Serum Concentration Versus Time Curve Using the Trapezoidal Method During a Dose Interval (AUC0-t) of Sarilumab at Week 12
The AUC0-t was defined as area under the concentration in serum versus time curve calculated using the trapezoidal method during a dose interval (tau). The values reported are mean and standard deviation.
Time frame: Pre-dose on Days 1, 3, 5, 8, 12 and Weeks 2, 4, 8 and 12
Concentration Before Treatment Administration During Repeated Dosing (Ctrough) of Sarilumab at Week 12
The Ctrough was defined as concentration observed before treatment administration during repeated dosing from baseline to Week 12. The values reported are mean and standard deviation.
Time frame: Pre-dose on Days 1, 3, 5, 8, 12 and Weeks 2, 4, 8 and 12
Cohorts 1 and 3: Change From Baseline in High-Sensitivity C-reactive Protein (Hs-CRP) at Week 12
Serum concentrations of hs-CRP was determined to assess the Pharmacodynamic (PD) effects of sarilumab. The values reported are mean and standard deviation.
Time frame: Baseline (Day 1) and Week 12
Cohort 2: Change From Baseline in High-Sensitivity C-reactive Protein at Weeks 12, 24, 48, 96, and 156
Serum concentrations of hs-CRP was determined to assess the PD effects of sarilumab. The values reported are mean and standard deviation.
Time frame: Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156
Change From Baseline in Interleukin-6 (IL-6) at Week 12
Serum concentrations of IL-6 was determined to assess the PD effects of sarilumab. The values reported are mean and standard deviation.
Time frame: Baseline (Day 1) and Week 12
Change From Baseline in Total Soluble Interleukin-6 Receptor (sIL-6R) at Week 12
Serum concentrations of sIL-6R was determined to assess the PD effects of sarilumab. The values reported are mean and standard deviation.
Time frame: Baseline (Day 1) and Week 12
Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology (JIA ACR) 30 Response at Week 12
JIA ACR30 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 30% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
Time frame: Week 12
Cohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 30 Response at Weeks 12, 24, 48, 96, and 156
JIA ACR30 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 30% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
Time frame: Weeks 12, 24, 48, 96, and 156
Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 50 Response at Week 12
JIA ACR50 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 50% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
Time frame: Week 12
Cohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 50 Response at Weeks 12, 24, 48, 96, and 156
JIA ACR50 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 50% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
Time frame: Weeks 12, 24, 48, 96, and 156
Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 70 Response at Week 12
JIA ACR70 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 70% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
Time frame: Week 12
Cohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 70 Response at Weeks 12, 24, 48, 96, and 156
JIA ACR70 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 70% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
Time frame: Weeks 12, 24, 48, 96, and 156
Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 90 Response at Week 12
JIA ACR90 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 90% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
Time frame: Week 12
Cohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 90 Response at Weeks 12, 24, 48, 96, and 156
JIA ACR90 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 90% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
Time frame: Weeks 12, 24, 48, 96, and 156
Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 100 Response at Week 12
JIA ACR100 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 100% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
Time frame: Week 12
Cohort 2: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 100 Response at Weeks 12, 24, 48, 96, and 156
JIA ACR100 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 100% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
Time frame: Weeks 12, 24, 48, 96, and 156
Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Activity Joint Count-71, at Week 12
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using visual analog scale (VAS), Childhood Health Questionnaire Disability Index (CHAQ-DI) and hs-CRP. Activity joint count-71 was calculated as sum (joints with active arthritis)\*(71/number of joints with assessment).
Time frame: Baseline (Day 1) and Week 12
Cohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Activity Joint Count-71, at Weeks 12, 24, 48, 96, and 156
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Activity joint count-71 was calculated as sum (joints with active arthritis)\*(71/number of joints with assessment).
Time frame: Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156
Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Limited Motion Joint Count, at Week 12
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Limited motion joint count was calculated as sum (joints with limited motion)\*(67/number of joints with assessment).
Time frame: Baseline (Day 1) and Week 12
Cohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Limited Motion Joint Count, at Weeks 12, 24, 48, 96, and 156
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Limited motion joint count was calculated as sum (joints with limited motion)\*(67/number of joints with assessment).
Time frame: Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156
Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Childhood Health Assessment Questionnaire Disability Index, at Week 12
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. The CHAQ questionnaire consists of 30 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain is scored on a 4 point scale ranges from 0 to 3: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). An additional response of "not applicable" is available to indicate activities the participant is unable to perform because he/she is too young. The CHAQ-DI total score is the sum of the domain scores divided by the number of domains that have a non-missing score. This overall score ranges from 0 (best) to 3 (worst). Higher scores indicate worse outcome.
Time frame: Baseline (Day 1) and Week 12
Cohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Childhood Health Assessment Questionnaire Disability Index, at Weeks 12, 24, 48, 96, and 156
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. The CHAQ questionnaire consists of 30 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain is scored on a 4 point scale ranges from 0 to 3: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). An additional response of "not applicable" is available to indicate activities the participant is unable to perform because he/she is too young. The CHAQ-DI total score is the sum of the domain scores divided by the number of domains that have a non-missing score. This overall score ranges from 0 (best) to 3 (worst). Higher scores indicate worse outcome.
Time frame: Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156
Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, C-Reactive Protein, at Week 12
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Serum concentrations of hs-CRP was determined to assess the PD effects of sarilumab.
Time frame: Baseline (Day 1) and Week 12
Cohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, C-Reactive Protein, at Weeks 12, 24, 48, 96, and 156
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Serum concentrations of hs-CRP was determined to assess the PD effects of sarilumab.
Time frame: Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156
Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Physician Global Assessment of Disease Activity, at Week 12
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Physician global assessment of disease activity was assessed on an anchored 100 mm horizontal VAS score ranging from 0 to 10 where 0 is considered the best disease activity (no disease activity) and 10 the worst (most disease activity). Higher scores indicate worse outcome.
Time frame: Baseline (Day 1) and Week 12
Cohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Physician Global Assessment of Disease Activity, at Weeks 12, 24, 48, 96, and 156
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Physician global assessment of disease activity was assessed on an anchored 100 mm horizontal VAS score ranging from 0 to 10 where 0 is considered the best disease activity (no disease activity) and 10 the worst (most disease activity). Higher scores indicate worse outcome.
Time frame: Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156
Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Participant/Parent Assessment of Overall Well-Being, at Week 12
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Participant/parent assessment of overall well-being was rated on an anchored 100 mm horizontal VAS score ranging from 0 to 10 where 0 is considered the best disease activity (no disease activity) and 10 the worst (most disease activity). Higher scores indicate worse outcome.
Time frame: Baseline (Day 1) and Week 12
Cohort 2: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Participant/Parent Assessment of Overall Well-Being, at Weeks 12, 24, 48, 96, and 156
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Participant/parent assessment of overall well-being was rated on an anchored 100 mm horizontal VAS score ranging from 0 to 10 where 0 is considered the best disease activity (no disease activity) and 10 the worst (most disease activity). Higher scores indicate worse outcome.
Time frame: Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156
Cohorts 1 and 3: Mean Change From Baseline in Juvenile Arthritis Disease Activity Score (JADAS-27) at Week 12
The JADAS is used for assessment of disease activity, and it includes 4 measures: Physician global assessment of disease activity (VAS range: 0 to10; where 0= no activity and 10= maximum activity), parent/participant global assessment of well-being (VAS range: 0 to 10; where 0= no activity and10= maximum activity), count of joints with active disease (range: 0 to 27; where 0= no activity and 27= maximum activity), and index of inflammation determined by hs-CRP or ESR (normalized scale range: 0 to 10; where 0= no disease activity and 10= maximum disease activity). The JADAS total score is calculated as the simple sum of the scores of its 4 components. The total score ranges from 0 to 57 where 0= no disease activity and 57= maximum disease activity. Higher scores indicate higher disease activity. Clinical JADAS-27 is without CRP or ESR component and score ranges from 0 to 47 where 0= no disease activity and 47= maximum disease activity.
Time frame: Baseline (Day 1) and Week 12
Cohort 2: Mean Change From Baseline in Juvenile Arthritis Disease Activity Score at Weeks 12, 24, 48, 96, and 156
The JADAS is used for assessment of disease activity, and it includes 4 measures: Physician global assessment of disease activity (VAS range: 0 to10; where 0= no activity and 10= maximum activity), parent/participant global assessment of well-being (VAS range: 0 to 10; where 0= no activity and10= maximum activity), count of joints with active disease (range: 0 to 27; where 0= no activity and 27= maximum activity), and index of inflammation determined by hs-CRP or ESR (normalized scale range: 0 to 10; where 0= no disease activity and 10= maximum disease activity). The JADAS total score is calculated as the simple sum of the scores of its 4 components. The total score ranges from 0 to 57 where 0= no disease activity and 57= maximum disease activity. Higher scores indicate higher disease activity. Clinical JADAS-27 is without CRP or ESR component and score ranges from 0 to 47 where 0= no disease activity and 47= maximum disease activity.
Time frame: Baseline (Day 1) and Weeks 12, 24, 48, 96, and 156
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs)
An adverse events (AEs) is any untoward medical occurrence in a participant or in a clinical investigation participant administered a medicinal product and which does not necessarily have a causal relationship with the study treatment. An SAE is any untoward medical occurrence that at any dose results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or is an important medical event. TEAEs are defined as AEs that develop or worsen during the on-treatment period \[that is, from the time of first dose of study treatment up to 6 weeks after the last administration of the study treatment\].
Time frame: From the first administration of study treatment (Day 1) up to end of treatment period, maximum of 156 weeks for portions 1 and 2 and 96 weeks for portion 3
Number of Participants With Local Site Reactions
Participants were observed for at least 30 minutes after each study treatment administration either on site or at home and any local reactions were noted in the diary regardless of being clinically significant.
Time frame: From the first administration of study treatment (Day 1) up to end of treatment period, maximum of 156 weeks for portions 1 and 2 and 96 weeks for portion 3
Group A: \>=30kg and \<=60kg and Group B: \<30kg and \>=10kg. Portion 1 of study enrolled participants into 3 dosing regimens (Cohort 1, 2 and 3). Cohort 1: dose capped at 150mg q2w (Group A:2mg/kg q2w; Group B:2.5mg/kg q2w). Cohort 2: dose capped at 200mg q2w (Group A:3mg/kg q2w; Group B:4mg/kg q2w). Cohort 3: dose capped at 150mg qw (Group A:2mg/kg qw; Group B:2.5mg/kg qw). All 3 cohorts in Portion 1 received 12-week core treatment phase and eligible participants entered 144-week extension phase.
| Milestone | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|---|---|
| Started | 7 | 6 | 43 | 31 | 6 | 9 |
| Treated | 7 | 6 | 42 | 31 | 6 | 9 |
| Completed | 6 | 6 | 38 | 27 | 6 | 7 |
| Not completed | 1 | 0 | 5 | 4 | 0 | 2 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by parent/guardian | 0 | 0 | 2 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 3 | 0 | 0 | 0 |
The Cmax was defined as maximum serum concentration. The values reported are mean and standard deviation.
| milligram per liter (mg/L) | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|---|---|
| Maximum Serum Concentration (Cmax) of Sarilumab at Week 12 | 7.57 ± 4.14 | 13.7 ± 2.52 | 22.0 ± 8.07 | 33.6 ± 7.16 | 32.0 ± 7.27 | 31.0 ± 7.98 |
The AUC0-t was defined as area under the concentration in serum versus time curve calculated using the trapezoidal method during a dose interval (tau). The values reported are mean and standard deviation.
| day*mg/L | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|---|---|
| Area Under the Serum Concentration Versus Time Curve Using the Trapezoidal Method During a Dose Interval (AUC0-t) of Sarilumab at Week 12 | 61.4 ± 25.2 | 106 ± 36.8 | 212 ± 77.2 | 318 ± 90.0 | 202 ± 55.0 | 192 ± 60.7 |
The Ctrough was defined as concentration observed before treatment administration during repeated dosing from baseline to Week 12. The values reported are mean and standard deviation.
| mg/L | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|---|---|
| Concentration Before Treatment Administration During Repeated Dosing (Ctrough) of Sarilumab at Week 12 | 1.30 ± 0.952 | 1.32 ± 1.27 | 5.76 ± 3.57 | 9.88 ± 5.42 | 22.2 ± 7.12 | 23.2 ± 8.28 |
Serum concentrations of hs-CRP was determined to assess the Pharmacodynamic (PD) effects of sarilumab. The values reported are mean and standard deviation.
| mg/L | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|
| Cohorts 1 and 3: Change From Baseline in High-Sensitivity C-reactive Protein (Hs-CRP) at Week 12 | -1.00 ± 2.53 | -0.52 ± 3.64 | -5.71 ± 8.90 | -6.83 ± 11.74 |
Serum concentrations of hs-CRP was determined to assess the PD effects of sarilumab. The values reported are mean and standard deviation.
| mg/L | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg |
|---|---|---|
| Week 12 | -3.54 ± 33.57 | -20.66 ± 48.35 |
| Week 24 | -8.54 ± 19.17 | -11.72 ± 23.54 |
| Week 48 | -9.93 ± 21.60 | -12.57 ± 24.23 |
| Week 96 | -9.39 ± 21.65 | -13.88 ± 25.96 |
| Week 156 | -5.10 ± 14.68 | -12.30 ± 26.69 |
Serum concentrations of IL-6 was determined to assess the PD effects of sarilumab. The values reported are mean and standard deviation.
| nanogram (ng)/L | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|---|---|
| Change From Baseline in Interleukin-6 (IL-6) at Week 12 | 1.27 ± 9.79 | 13.65 ± 18.20 | 43.71 ± 113.42 | 11.36 ± 35.81 | 66.21 ± 86.21 | 9.20 ± 26.50 |
Serum concentrations of sIL-6R was determined to assess the PD effects of sarilumab. The values reported are mean and standard deviation.
| ng/mL | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|---|---|
| Change From Baseline in Total Soluble Interleukin-6 Receptor (sIL-6R) at Week 12 | 40.09 ± 49.75 | 101.50 ± 129.59 | 316.77 ± 129.29 | 388.33 ± 185.82 | 535.76 ± 98.12 | 582.95 ± 149.52 |
JIA ACR30 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 30% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
| percentage of participants with response | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|
| Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology (JIA ACR) 30 Response at Week 12 | 100 | 100 | 100 | 100 |
JIA ACR30 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 30% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
| percentage of participants with response | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg |
|---|---|---|
| Week 12 | 100 | 100 |
| Week 24 | 100 | 100 |
| Week 48 | 100 | 100 |
| Week 96 | 97.2 | 100 |
| Week 156 | 94.1 | 100 |
JIA ACR50 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 50% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
| percentage of participants with response | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|
| Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 50 Response at Week 12 | 80.0 | 100 | 100 | 100 |
JIA ACR50 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 50% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
| percentage of participants with response | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg |
|---|---|---|
| Week 12 | 94.9 | 96.6 |
| Week 24 | 100 | 100 |
| Week 48 | 100 | 100 |
| Week 96 | 97.2 | 100 |
| Week 156 | 94.1 | 100 |
JIA ACR70 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 70% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
| percentage of participants with response | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|
| Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 70 Response at Week 12 | 60.0 | 40.0 | 100 | 100 |
JIA ACR70 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 70% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
| percentage of participants with response | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg |
|---|---|---|
| Week 12 | 74.4 | 89.7 |
| Week 24 | 87.2 | 96.3 |
| Week 48 | 89.5 | 100 |
| Week 96 | 97.2 | 100 |
| Week 156 | 94.1 | 100 |
JIA ACR90 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 90% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
| percentage of participants with response | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|
| Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 90 Response at Week 12 | 60.0 | 20.0 | 66.7 | 60.0 |
JIA ACR90 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 90% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
| percentage of participants with response | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg |
|---|---|---|
| Week 12 | 43.6 | 48.3 |
| Week 24 | 64.1 | 74.1 |
| Week 48 | 68.4 | 88.5 |
| Week 96 | 80.6 | 95.8 |
| Week 156 | 76.5 | 100 |
JIA ACR100 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 100% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
| percentage of participants with response | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|
| Cohorts 1 and 3: Percentage of Participants With Juvenile Idiopatic Arthritis American College of Rheumatology 100 Response at Week 12 | 0 | 0 | 33.3 | 40.0 |
JIA ACR100 response was defined as a participant with at least 3 out of the 6 JIA core set variables with \>= 100% improvement from baseline with no more than 1 of the remaining variables worsened by \>= 30%.
| percentage of participants with response | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg |
|---|---|---|
| Week 12 | 12.8 | 24.1 |
| Week 24 | 23.1 | 48.1 |
| Week 48 | 42.1 | 53.8 |
| Week 96 | 47.2 | 70.8 |
| Week 156 | 52.9 | 87.5 |
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using visual analog scale (VAS), Childhood Health Questionnaire Disability Index (CHAQ-DI) and hs-CRP. Activity joint count-71 was calculated as sum (joints with active arthritis)\*(71/number of joints with assessment).
| joint | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|
| Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Activity Joint Count-71, at Week 12 | -14.40 ± 2.159 | -11.20 ± 2.871 | -16.50 ± 4.137 | -14.40 ± 5.573 |
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Activity joint count-71 was calculated as sum (joints with active arthritis)\*(71/number of joints with assessment).
| joint | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg |
|---|---|---|
| Week 12 | -15.15 ± 1.511 | -12.38 ± 1.519 |
| Week 24 | -16.66 ± 1.497 | -13.26 ± 1.575 |
| Week 48 | -17.24 ± 1.547 | -13.73 ± 1.618 |
| Week 96 | -16.47 ± 1.682 | -13.79 ± 1.751 |
| Week 156 | -18.65 ± 2.334 | -13.88 ± 2.495 |
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Limited motion joint count was calculated as sum (joints with limited motion)\*(67/number of joints with assessment).
| joint | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|
| Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Limited Motion Joint Count, at Week 12 | -7.80 ± 2.083 | -5.80 ± 2.267 | -7.83 ± 2.600 | -13.00 ± 4.219 |
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Limited motion joint count was calculated as sum (joints with limited motion)\*(67/number of joints with assessment).
| joint | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg |
|---|---|---|
| Week 12 | -9.71 ± 1.249 | -9.21 ± 1.540 |
| Week 24 | -10.40 ± 1.330 | -10.63 ± 1.559 |
| Week 48 | -10.99 ± 1.498 | -10.73 ± 1.525 |
| Week 96 | -11.14 ± 1.661 | -10.42 ± 1.493 |
| Week 156 | -11.29 ± 2.203 | -11.81 ± 2.550 |
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. The CHAQ questionnaire consists of 30 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain is scored on a 4 point scale ranges from 0 to 3: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). An additional response of "not applicable" is available to indicate activities the participant is unable to perform because he/she is too young. The CHAQ-DI total score is the sum of the domain scores divided by the number of domains that have a non-missing score. This overall score ranges from 0 (best) to 3 (worst). Higher scores indicate worse outcome.
| units on a scale | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|
| Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Childhood Health Assessment Questionnaire Disability Index, at Week 12 | -0.80 ± 0.242 | -1.08 ± 0.239 | -0.42 ± 0.173 | -0.75 ± 0.213 |
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. The CHAQ questionnaire consists of 30 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities. Each domain is scored on a 4 point scale ranges from 0 to 3: 0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do). An additional response of "not applicable" is available to indicate activities the participant is unable to perform because he/she is too young. The CHAQ-DI total score is the sum of the domain scores divided by the number of domains that have a non-missing score. This overall score ranges from 0 (best) to 3 (worst). Higher scores indicate worse outcome.
| units on a scale | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg |
|---|---|---|
| Week 12 | -0.77 ± 0.092 | -0.74 ± 0.113 |
| Week 24 | -0.90 ± 0.096 | -0.95 ± 0.132 |
| Week 48 | -0.88 ± 0.084 | -1.08 ± 0.119 |
| Week 96 | -0.92 ± 0.109 | -1.13 ± 0.136 |
| Week 156 | -1.07 ± 0.163 | -1.20 ± 0.169 |
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Serum concentrations of hs-CRP was determined to assess the PD effects of sarilumab.
| mg/L | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|
| Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, C-Reactive Protein, at Week 12 | -1.00 ± 1.130 | -1.67 ± 1.139 | -5.71 ± 3.633 | -2.54 ± 1.845 |
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Serum concentrations of hs-CRP was determined to assess the PD effects of sarilumab.
| mg/L | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg |
|---|---|---|
| Week 12 | -3.84 ± 5.437 | -20.66 ± 9.304 |
| Week 24 | -8.54 ± 3.151 | -11.72 ± 4.371 |
| Week 48 | -9.93 ± 3.505 | -12.57 ± 4.664 |
| Week 96 | -9.39 ± 3.608 | -13.88 ± 5.414 |
| Week 156 | -5.10 ± 3.671 | -12.30 ± 6.672 |
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Physician global assessment of disease activity was assessed on an anchored 100 mm horizontal VAS score ranging from 0 to 10 where 0 is considered the best disease activity (no disease activity) and 10 the worst (most disease activity). Higher scores indicate worse outcome.
| units on a scale | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|
| Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Physician Global Assessment of Disease Activity, at Week 12 | -3.56 ± 0.969 | -6.30 ± 0.397 | -4.55 ± 0.509 | -5.68 ± 1.163 |
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Physician global assessment of disease activity was assessed on an anchored 100 mm horizontal VAS score ranging from 0 to 10 where 0 is considered the best disease activity (no disease activity) and 10 the worst (most disease activity). Higher scores indicate worse outcome.
| units on a scale | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg |
|---|---|---|
| Week 12 | -4.50 ± 0.248 | -4.09 ± 0.367 |
| Week 24 | -4.99 ± 0.237 | -5.01 ± 0.341 |
| Week 48 | -5.27 ± 0.263 | -5.25 ± 0.321 |
| Week 96 | -5.30 ± 0.306 | -5.35 ± 0.347 |
| Week 156 | -5.66 ± 0.396 | -5.73 ± 0.437 |
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Participant/parent assessment of overall well-being was rated on an anchored 100 mm horizontal VAS score ranging from 0 to 10 where 0 is considered the best disease activity (no disease activity) and 10 the worst (most disease activity). Higher scores indicate worse outcome.
| units on a scale | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|
| Cohorts 1 and 3: Change From Baseline in Juvenile Idiopatic Arthritis American College of Rheumatology Component, Participant/Parent Assessment of Overall Well-Being, at Week 12 | -3.30 ± 1.014 | -3.16 ± 1.364 | -3.05 ± 0.992 | -5.00 ± 0.969 |
The JIA ACR components included joints with active arthritis (0 to 71 joints), joints with limited motion (0 to 67 joints), physician global assessment of disease activity and participant/parent assessment of overall well-being using VAS, CHAQ-DI and hs-CRP. Participant/parent assessment of overall well-being was rated on an anchored 100 mm horizontal VAS score ranging from 0 to 10 where 0 is considered the best disease activity (no disease activity) and 10 the worst (most disease activity). Higher scores indicate worse outcome.
| units on a scale | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg |
|---|---|---|
| Week 12 | -3.73 ± 0.335 | -4.01 ± 0.435 |
| Week 24 | -4.38 ± 0.313 | -4.39 ± 0.475 |
| Week 48 | -4.21 ± 0.356 | -4.64 ± 0.510 |
| Week 96 | -4.36 ± 0.387 | -5.09 ± 0.521 |
| Week 156 | -4.19 ± 0.738 | -5.01 ± 0.636 |
The JADAS is used for assessment of disease activity, and it includes 4 measures: Physician global assessment of disease activity (VAS range: 0 to10; where 0= no activity and 10= maximum activity), parent/participant global assessment of well-being (VAS range: 0 to 10; where 0= no activity and10= maximum activity), count of joints with active disease (range: 0 to 27; where 0= no activity and 27= maximum activity), and index of inflammation determined by hs-CRP or ESR (normalized scale range: 0 to 10; where 0= no disease activity and 10= maximum disease activity). The JADAS total score is calculated as the simple sum of the scores of its 4 components. The total score ranges from 0 to 57 where 0= no disease activity and 57= maximum disease activity. Higher scores indicate higher disease activity. Clinical JADAS-27 is without CRP or ESR component and score ranges from 0 to 47 where 0= no disease activity and 47= maximum disease activity.
| units on a scale | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|
| JADAS-27-ESR: Week 12 | -15.4 ± 2.98 | -19.1 ± 3.05 | -20.0 ± 3.82 | -19.4 ± 6.01 |
| JADAS-27-CRP: Week 12 | -16.0 ± 2.78 | -18.1 ± 2.62 | -18.5 ± 3.42 | -21.1 ± 4.96 |
| Clinical JADAS-27: Week 12 | -16.1 ± 2.77 | -18.1 ± 2.62 | -18.3 ± 3.28 | -21.1 ± 4.96 |
The JADAS is used for assessment of disease activity, and it includes 4 measures: Physician global assessment of disease activity (VAS range: 0 to10; where 0= no activity and 10= maximum activity), parent/participant global assessment of well-being (VAS range: 0 to 10; where 0= no activity and10= maximum activity), count of joints with active disease (range: 0 to 27; where 0= no activity and 27= maximum activity), and index of inflammation determined by hs-CRP or ESR (normalized scale range: 0 to 10; where 0= no disease activity and 10= maximum disease activity). The JADAS total score is calculated as the simple sum of the scores of its 4 components. The total score ranges from 0 to 57 where 0= no disease activity and 57= maximum disease activity. Higher scores indicate higher disease activity. Clinical JADAS-27 is without CRP or ESR component and score ranges from 0 to 47 where 0= no disease activity and 47= maximum disease activity.
| units on a scale | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg |
|---|---|---|
| JADAS-27-ESR: Week 12 | -18.9 ± 1.46 | -16.9 ± 1.51 |
| JADAS-27-ESR: Week 24 | -21.9 ± 1.32 | -18.3 ± 1.72 |
| JADAS-27-ESR: Week 48 | -22.3 ± 1.45 | -19.4 ± 1.61 |
| JADAS-27-ESR: Week 96 | -22.4 ± 1.69 | -20.4 ± 1.84 |
| JADAS-27-ESR: Week 156 | -23.2 ± 2.06 | -20.6 ± 2.57 |
| JADAS-27-CRP: Week 12 | -18.2 ± 1.26 | -16.3 ± 1.42 |
| JADAS-27-CRP: Week 24 | -20.9 ± 1.20 | -18.8 ± 1.53 |
| JADAS-27-CRP: Week 48 | -21.6 ± 1.23 | -19.4 ± 1.58 |
| JADAS-27-CRP: Week 96 | -21.9 ± 1.58 | -20.1 ± 1.50 |
| JADAS-27-CRP: Week 156 | -21.8 ± 2.01 | -20.2 ± 2.24 |
| Clinical JADAS-27: Week 12 | -17.9 ± 1.19 | -16.0 ± 1.32 |
| Clinical JADAS-27: Week 24 | -20.5 ± 1.14 | -18.0 ± 1.46 |
| Clinical JADAS-27: Week 48 | -21.0 ± 1.22 | -18.8 ± 1.49 |
| Clinical JADAS-27: Week 96 | -21.2 ± 1.52 | -19.5 ± 1.60 |
| Clinical JADAS-27: Week 156 | -21.2 ± 1.85 | -19.3 ± 2.14 |
An adverse events (AEs) is any untoward medical occurrence in a participant or in a clinical investigation participant administered a medicinal product and which does not necessarily have a causal relationship with the study treatment. An SAE is any untoward medical occurrence that at any dose results in death or is life-threatening or requires inpatient hospitalization or prolongation of existing hospitalization or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect or is an important medical event. TEAEs are defined as AEs that develop or worsen during the on-treatment period \[that is, from the time of first dose of study treatment up to 6 weeks after the last administration of the study treatment\].
| Participants | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|---|---|
| Any TEAE | 7 | 6 | 40 | 30 | 5 | 9 |
| Any treatment emergent SAE | 2 | 0 | 3 | 3 | 0 | 0 |
Participants were observed for at least 30 minutes after each study treatment administration either on site or at home and any local reactions were noted in the diary regardless of being clinically significant.
| Participants | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|---|---|
| Number of Participants With Local Site Reactions | 1 | 0 | 21 | 19 | 3 | 1 |
Collected over From the first administration of study treatment (Day 1) up to end of study, maximum of 162 weeks for portions 1 and 2 and 102 weeks for portion 3.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: >= 30 kg and <= 60 kg | 0/7 (0%) | 2/7 (28.6%) | 7/7 (100%) |
| Cohort 2 (From Baseline): >= 30 kg and <= 60 kg | 0/42 (0%) | 3/42 (7.1%) | 39/42 (92.9%) |
| Cohort 1 Portion 1, Post Dose-adjustment From Dose 1: >= 30 kg and <= 60 kg | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| Cohort 3 Portion 1, Post Dose-adjustment From Dose 3: >= 30 kg and <= 60 kg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Cohort 3: >= 30 kg and <= 60 kg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Cohort 1: < 30 kg and >= 10 kg | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Cohort 2 (From Baseline): < 30 kg and >= 10 kg | 0/31 (0%) | 3/31 (9.7%) | 29/31 (93.5%) |
| Cohort 1 Portion 1, Post Dose-adjustment From Dose 1: < 30 kg and >= 10 kg | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Cohort 3 Portion 1, Post Dose-adjustment From Dose 3: < 30 kg and >= 10 kg | 0/5 (0%) | 0/5 (0%) | 5/5 (100%) |
| Cohort 3: < 30 kg and >= 10 kg | 0/9 (0%) | 0/9 (0%) | 9/9 (100%) |
| Event | Cohort 1: >= 30 kg and <= 60 kg | Cohort 2 (From Baseline): >= 30 kg and <= 60 kg | Cohort 1 Portion 1, Post Dose-adjustment From Dose 1: >= 30 kg and <= 60 kg | Cohort 3 Portion 1, Post Dose-adjustment From Dose 3: >= 30 kg and <= 60 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 2 (From Baseline): < 30 kg and >= 10 kg | Cohort 1 Portion 1, Post Dose-adjustment From Dose 1: < 30 kg and >= 10 kg | Cohort 3 Portion 1, Post Dose-adjustment From Dose 3: < 30 kg and >= 10 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|---|---|---|---|---|---|
| Infectious MononucleosisInfections and infestations | 1/7 | 0/42 | 0/4 | 0/6 | 0/6 | 0/6 | 0/31 | 0/5 | 0/5 | 0/9 |
| SyncopeNervous system disorders | 1/7 | 0/42 | 0/4 | 0/6 | 0/6 | 0/6 | 0/31 | 0/5 | 0/5 | 0/9 |
| Inguinal HerniaGastrointestinal disorders | 0/7 | 0/42 | 0/4 | 0/6 | 0/6 | 0/6 | 1/31 | 0/5 | 0/5 | 0/9 |
| Pancreatic PseudocystGastrointestinal disorders | 0/7 | 0/42 | 0/4 | 0/6 | 0/6 | 0/6 | 1/31 | 0/5 | 0/5 | 0/9 |
| Pancreatitis AcuteGastrointestinal disorders | 0/7 | 0/42 | 0/4 | 0/6 | 0/6 | 0/6 | 1/31 | 0/5 | 0/5 | 0/9 |
| Bone TuberculosisInfections and infestations | 0/7 | 0/42 | 0/4 | 0/6 | 0/6 | 0/6 | 1/31 | 0/5 | 0/5 | 0/9 |
| Tonsillar HypertrophyRespiratory, thoracic and mediastinal disorders | 0/7 | 0/42 | 0/4 | 0/6 | 0/6 | 0/6 | 1/31 | 0/5 | 0/5 | 0/9 |
| Acute SinusitisInfections and infestations | 0/7 | 1/42 | 0/4 | 0/6 | 0/6 | 0/6 | 0/31 | 0/5 | 0/5 | 0/9 |
| Ligament RuptureInjury, poisoning and procedural complications | 0/7 | 1/42 | 0/4 | 0/6 | 0/6 | 0/6 | 0/31 | 0/5 | 0/5 | 0/9 |
| Meniscus InjuryInjury, poisoning and procedural complications | 0/7 | 1/42 | 0/4 | 0/6 | 0/6 | 0/6 | 0/31 | 0/5 | 0/5 | 0/9 |
| Event | Cohort 1: >= 30 kg and <= 60 kg | Cohort 2 (From Baseline): >= 30 kg and <= 60 kg | Cohort 1 Portion 1, Post Dose-adjustment From Dose 1: >= 30 kg and <= 60 kg | Cohort 3 Portion 1, Post Dose-adjustment From Dose 3: >= 30 kg and <= 60 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 2 (From Baseline): < 30 kg and >= 10 kg | Cohort 1 Portion 1, Post Dose-adjustment From Dose 1: < 30 kg and >= 10 kg | Cohort 3 Portion 1, Post Dose-adjustment From Dose 3: < 30 kg and >= 10 kg | Cohort 3: < 30 kg and >= 10 kg |
|---|---|---|---|---|---|---|---|---|---|---|
| Upper Respiratory Tract InfectionInfections and infestations | 4/7 | 6/42 | 3/4 | 1/6 | 2/6 | 2/6 | 3/31 | 0/5 | 1/5 | 2/9 |
| NeutropeniaBlood and lymphatic system disorders | 3/7 | 10/42 | 1/4 | 0/6 | 1/6 | 1/6 | 15/31 | 2/5 | 0/5 | 6/9 |
| NasopharyngitisInfections and infestations | 0/7 | 11/42 | 0/4 | 4/6 | 3/6 | 1/6 | 17/31 | 0/5 | 3/5 | 3/9 |
| Ligament SprainInjury, poisoning and procedural complications | 1/7 | 2/42 | 2/4 | 0/6 | 0/6 | 0/6 | 0/31 | 0/5 | 0/5 | 0/9 |
| VomitingGastrointestinal disorders | 0/7 | 2/42 | 0/4 | 0/6 | 1/6 | 0/6 | 3/31 | 2/5 | 2/5 | 1/9 |
| PharyngitisInfections and infestations | 1/7 | 6/42 | 0/4 | 0/6 | 0/6 | 2/6 | 1/31 | 2/5 | 0/5 | 0/9 |
| RhinitisInfections and infestations | 2/7 | 4/42 | 0/4 | 0/6 | 0/6 | 1/6 | 3/31 | 1/5 | 2/5 | 3/9 |
| Dermatitis AllergicSkin and subcutaneous tissue disorders | 0/7 | 0/42 | 0/4 | 0/6 | 0/6 | 0/6 | 1/31 | 2/5 | 0/5 | 0/9 |
| PneumoniaInfections and infestations | 0/7 | 0/42 | 0/4 | 0/6 | 2/6 | 0/6 | 2/31 | 0/5 | 0/5 | 0/9 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/7 | 2/42 | 0/4 | 0/6 | 0/6 | 2/6 | 3/31 | 0/5 | 0/5 | 0/9 |
All treated population included participants who signed informed consent and received at least 1 dose of the study treatment.
| Age, Continuous(years) | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg | Total |
|---|---|---|---|---|---|---|---|
| Mean | 12.3 ± 3.3 | 6.5 ± 3.2 | 12.6 ± 3.0 | 5.4 ± 3.1 | 13.7 ± 3.0 | 4.8 ± 2.4 | 9.4 ± 4.7 |
| Sex: Female, Male(Participants) | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg | Total |
|---|---|---|---|---|---|---|---|
| Female | 5 | 5 | 35 | 23 | 3 | 6 | 77 |
| Male | 2 | 1 | 7 | 8 | 3 | 3 | 24 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: >= 30 kg and <= 60 kg | Cohort 1: < 30 kg and >= 10 kg | Cohort 2: >= 30 kg and <= 60 kg | Cohort 2: < 30 kg and >= 10 kg | Cohort 3: >= 30 kg and <= 60 kg | Cohort 3: < 30 kg and >= 10 kg | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 6 | 3 | 39 | 28 | 4 | 8 | 88 |
| Not Reported | 0 | 1 | 2 | 3 | 0 | 1 | 7 |
| Unknown | 1 | 2 | 0 | 0 | 2 | 0 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Ran from Sep 2016 to primary completion in Apr 2022, 67 months.
Results were first posted in Oct 2024, 2 years 6 months after primary completion. A results delay was requested in Apr 2023.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sarilumab